|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0000098,
umls-concept:C0007634,
umls-concept:C0022023,
umls-concept:C0037083,
umls-concept:C0162638,
umls-concept:C0205198,
umls-concept:C0205263,
umls-concept:C0205314,
umls-concept:C0332161,
umls-concept:C0439849,
umls-concept:C0445223,
umls-concept:C0662612,
umls-concept:C0679622,
umls-concept:C1527240,
umls-concept:C1552599,
umls-concept:C1704787
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2007-1-26
|
|
pubmed:abstractText |
Compound FLZ (cFLZ) is a synthetic novel derivative of natural squamosamide. Previous pharmacological study found that cFLZ improved the abnormal behavior and the decrease of dopamine content in striatum in 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) model mice. 1-Methyl 4-phenylpyridinium (MPP+) is the active metabolite of MPTP to cause Parkinsonism in experimental animals. The purpose of this paper was to further study the protective action of cFLZ against MPP+-induced apoptosis and alternations of related signaling transduction. The results indicated that cFLZ at concentrations of 0.1 microM and 1 microM prevented 100 microM MPP+-induced apoptosis of SH-SY5Y cells, and inhibited the release of cytochrome C and apoptosis-inducing factor (AIF), and the activation of caspase 3 and NF-kappaB as well as alpha-synuclein gene and protein expressions. The results suggest that cFLZ possesses potent neuroprotective activity and may be a potential anti-Parkinson's disease drug worthy for further study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1-Methyl-4-phenyl-1,2,3,6-tetrahydro...,
http://linkedlifedata.com/resource/pubmed/chemical/Benzeneacetamides,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Neurotoxins,
http://linkedlifedata.com/resource/pubmed/chemical/Phenols,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/alpha-Synuclein,
http://linkedlifedata.com/resource/pubmed/chemical/squamosamide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0028-3908
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
423-9
|
|
pubmed:dateRevised |
2010-6-7
|
|
pubmed:meshHeading |
pubmed-meshheading:17055540-1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine,
pubmed-meshheading:17055540-Analysis of Variance,
pubmed-meshheading:17055540-Apoptosis,
pubmed-meshheading:17055540-Benzeneacetamides,
pubmed-meshheading:17055540-Caspase 3,
pubmed-meshheading:17055540-Cell Line, Tumor,
pubmed-meshheading:17055540-Cell Survival,
pubmed-meshheading:17055540-Dose-Response Relationship, Drug,
pubmed-meshheading:17055540-Drug Interactions,
pubmed-meshheading:17055540-Gene Expression Regulation,
pubmed-meshheading:17055540-Humans,
pubmed-meshheading:17055540-Neuroblastoma,
pubmed-meshheading:17055540-Neurotoxins,
pubmed-meshheading:17055540-Phenols,
pubmed-meshheading:17055540-RNA, Messenger,
pubmed-meshheading:17055540-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17055540-Signal Transduction,
pubmed-meshheading:17055540-alpha-Synuclein
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells.
|
|
pubmed:affiliation |
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 1 Xian Nong Tan Street, Beijing 100050, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
